CA125、CA19.9、NSE 和 SCC 对 I 期非小细胞肺癌的预后价值有限。

The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department I of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, PR China.

出版信息

Cancer Biomark. 2011;10(3-4):155-62. doi: 10.3233/CBM-2012-0246.

DOI:10.3233/CBM-2012-0246

PMID:22674301

Abstract

OBJECTIVE

Amongst the current detections of tumor markers, measurement of serum tumor markers is the most convenient and the safest way. However, there are few promising serum tumor markers with confirmed prognostic value in NSCLC (non-small-cell lung cancer, NSCLC). Therefore, scientists only grafted the useful tumor markers, such as CA125, CA19.9, NSE, SCC, CEA and CYFRA21.1 which have been found in other solid tumors. However, previous reports about this issue remain controversial. This study is to analyze the prognostic values of these 6 markers in stage I NSCLC.

METHODS

One hundred and sixty four patients with stage I NSCLC who underwent operation by single-surgery-team in Department I of Thoracic Surgery, Peking University Cancer Hospital between March 2000 and March 2011 were included. These patients had measurement of CA125, CA19.9, NSE, SCC, CEA and CYFRA21.1 using electrochemiluminescence immunoassay one week before operation. The relationship between the level of these 6 tumor markers and long term survival rate was analyzed.

RESULTS

The positive rate for CA125, CA19.9, NSE, SCC, CEA and CYFRA 21.1 in the 121 adenocarcinoma patients was 5.7%, 5.7%, 18.3%, 5.3%, 18.3%, and 20.7% respectively; whereas 3.1%, 2.6%, 23.8%, 26.8%, 14.0%, and 42.9% in 43 non-adenocarcinoma patients, respectively. In univariate analysis, the overall 5 year survival rate of patients with elevated CYFRA21.1 level was lower than that of patients with normal level in ADC subgroup (54.5% vs. 83.8%, p < 0.05) and in all 164 cases (49.5% vs. 76.4%, p < 0.05). In multivariate analysis, the level of CYFRA21.1 was an independent prognostic factor. But the other 5 markers didn't show significant prognostic value.

CONCLUSIONS

We found that the prognostic values of CA125, CA19.9, NSE, and SCC for stage I NSCLC are limited. CYFRA21.1 might be a hopeful prognostic serum tumor marker for stage I NSCLC.

摘要

目的

在目前的肿瘤标志物检测中，检测血清肿瘤标志物是最方便、最安全的方法。然而，在非小细胞肺癌（NSCLC）中，具有明确预后价值的有前途的血清肿瘤标志物却很少。因此，科学家们只是将已经在其他实体瘤中发现的有用的肿瘤标志物，如 CA125、CA19.9、NSE、SCC、CEA 和 CYFRA21.1 等进行了嫁接。然而，之前关于这个问题的报告仍然存在争议。本研究旨在分析这 6 种标志物在 I 期 NSCLC 中的预后价值。

方法

选取 2000 年 3 月至 2011 年 3 月期间，在北京大学肿瘤医院胸外科 I 部接受单手术团队手术的 164 例 I 期 NSCLC 患者。这些患者在术前一周内使用电化学发光免疫分析法检测 CA125、CA19.9、NSE、SCC、CEA 和 CYFRA21.1。分析这 6 种肿瘤标志物水平与长期生存率的关系。

结果

在 121 例腺癌患者中，CA125、CA19.9、NSE、SCC、CEA 和 CYFRA21.1 的阳性率分别为 5.7%、5.7%、18.3%、5.3%、18.3%和 20.7%；而在 43 例非腺癌患者中，分别为 3.1%、2.6%、23.8%、26.8%、14.0%和 42.9%。单因素分析显示，CYFRA21.1 水平升高的患者在 ADC 亚组（54.5% vs. 83.8%，p < 0.05）和所有 164 例患者（54.5% vs. 76.4%，p < 0.05）中的总体 5 年生存率均低于 CYFRA21.1 水平正常的患者。多因素分析显示，CYFRA21.1 水平是独立的预后因素。但其他 5 个标志物均未显示出明显的预后价值。